Whitehawk Therapeutics' (WHWK) Sell (E+) Rating Reaffirmed at Weiss Ratings

Key Points

• Whitehawk Therapeutics' stock received a **"sell (e+)" rating** from Weiss Ratings, indicating continued bearish sentiment towards the company.
• The stock **traded down 6.3%** to $2.08 on Wednesday, with a market cap of $98.03 million and a significant **PE ratio of -34.67**.
• In its most recent earnings report, Whitehawk Therapeutics missed analysts' earnings expectations by reporting **($0.76) earnings per share** compared to a consensus of $0.49.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report)'s stock had its "sell (e+)" rating reiterated by analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other research firms have also recently commented on WHWK. Zacks Research upgraded Whitehawk Therapeutics to a "strong sell" rating in a research report on Monday, August 11th. Wall Street Zen cut Whitehawk Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. Two investment analysts have rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of "Sell".

Whitehawk Therapeutics Trading Down 6.3%

WHWK stock traded down $0.14 during midday trading on Wednesday, reaching $2.08. The stock had a trading volume of 60,892 shares, compared to its average volume of 146,139. The firm has a market cap of $98.03 million, a PE ratio of -34.67 and a beta of 0.58. The firm has a fifty day simple moving average of $1.83. Whitehawk Therapeutics has a 52-week low of $1.39 and a 52-week high of $3.81.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.49 by ($1.25). Whitehawk Therapeutics had a negative return on equity of 75.99% and a net margin of 99.42%.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.